GSTP1 DNA Methylation and Expression Status Is Indicative of 5-aza-2′-Deoxycytidine Efficacy in Human Prostate Cancer Cells

被引:35
作者
Chiam, Karen [1 ]
Centenera, Margaret M. [1 ]
Butler, Lisa M. [1 ]
Tilley, Wayne D. [1 ]
Bianco-Miotto, Tina [1 ]
机构
[1] Univ Adelaide, Dame Roma Mitchell Canc Res Labs, Discipline Med, Hanson Inst, Adelaide, SA, Australia
基金
英国医学研究理事会;
关键词
CPG ISLAND HYPERMETHYLATION; RISK MYELODYSPLASTIC SYNDROME; PROMOTER METHYLATION; BREAST-CANCER; GENE-EXPRESSION; PHASE-I; HYPOMETHYLATING AGENT; ANTINEOPLASTIC ACTION; L1210; LEUKEMIA; MOUSE MODEL;
D O I
10.1371/journal.pone.0025634
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
DNA methylation plays an important role in carcinogenesis and the reversibility of this epigenetic modification makes it a potential therapeutic target. To date, DNA methyltransferase inhibitors (DNMTi) have not demonstrated clinical efficacy in prostate cancer, with one of the major obstacles being the inability to monitor drug activity during the trial. Given the high frequency and specificity of GSTP1 DNA methylation in prostate cancer, we investigated whether GSTP1 is a useful marker of DNMTi treatment efficacy. LNCaP prostate cancer cells were treated with 5-aza-2'-deoxycytidine (5-aza-CdR) either with a single high dose (5-20 mu M), every alternate day (0.1-10 mu M) or daily (0.005-2.5 mu M). A daily treatment regimen with 5-aza-CdR was optimal, with significant suppression of cell proliferation achieved with doses of 0.05 mu M or greater (p<0.0001) and induction of cell death from 0.5 mu M (p<0.0001). In contrast, treatment with a single high dose of 20 mu M 5-aza-CdR inhibited cell proliferation but was not able to induce cell death. Demethylation of GSTP1 was observed with doses of 5-aza-CdR that induced significant suppression of cell proliferation (>= 0.05 mu M). Re-expression of the GSTP1 protein was observed only at doses of 5-aza-CdR (>= 0.5 mu M) associated with induction of cell death. Treatment of LNCaP cells with a more stable DNMTi, Zebularine required at least a 100-fold higher dose (>= 50 mu M) to inhibit proliferation and was less potent in inducing cell death, which corresponded to a lack of GSTP1 protein re-expression. We have shown that GSTP1 DNA methylation and protein expression status is correlated with DNMTi treatment response in prostate cancer cells. Since GSTP1 is methylated in nearly all prostate cancers, our results warrant its testing as a marker of epigenetic therapy response in future clinical trials. We conclude that the DNA methylation and protein expression status of GSTP1 are good indicators of DNMTi efficacy.
引用
收藏
页数:11
相关论文
共 60 条
[1]   Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy [J].
Bastian, PJ ;
Palapattu, GS ;
Lin, XH ;
Yegnasubramanian, S ;
Mangold, LA ;
Trock, B ;
Eisenberger, MA ;
Partin, AW ;
Nelson, WG .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :4037-4043
[2]  
Bender CM, 1999, MOL CELL BIOL, V19, P6690
[3]  
Bender CM, 1998, CANCER RES, V58, P95
[4]   Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development [J].
Bianco-Miotto, Tina ;
Chiam, Karen ;
Buchanan, Grant ;
Jindal, Shalini ;
Day, Tanya K. ;
Thomas, Mervyn ;
Pickering, Marie A. ;
O'Loughlin, Melissa A. ;
Ryan, Natalie K. ;
Raymond, Wendy A. ;
Horvath, Lisa G. ;
Kench, James G. ;
Stricker, Phillip D. ;
Marshall, Villis R. ;
Sutherland, Robert L. ;
Henshall, Susan M. ;
Gerald, William L. ;
Scher, Howard I. ;
Risbridger, Gail P. ;
Clements, Judith A. ;
Butler, Lisa M. ;
Tilley, Wayne D. ;
Horsfall, David J. ;
Ricciardelli, Carmela .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (10) :2611-2622
[5]   p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation [J].
Bott, SRJ ;
Arya, M ;
Kirby, RS ;
Williamson, M .
PROSTATE CANCER AND PROSTATIC DISEASES, 2005, 8 (04) :321-326
[6]   Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? [J].
Brothman, AR ;
Swanson, G ;
Maxwell, TM ;
Cui, J ;
Murphy, KJ ;
Herrick, J ;
Speights, VO ;
Isaac, J ;
Rohr, LR .
CANCER GENETICS AND CYTOGENETICS, 2005, 156 (01) :31-36
[7]   Inhibition of DNA methylation and reactivation of silenced genes by zebularine [J].
Cheng, JC ;
Matsen, CB ;
Gonzales, FA ;
Ye, W ;
Greer, S ;
Marquez, VE ;
Jones, PA ;
Selker, EU .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (05) :399-409
[8]   Decitabine: a historical review of the development of an epigenetic drug [J].
de Vos, D ;
van Overveld, W .
ANNALS OF HEMATOLOGY, 2005, 84 (Suppl 1) :3-8
[9]   Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer [J].
Dowsett, Mitch ;
Smith, Ian E. ;
Ebbs, Stephen R. ;
Dixon, J. Michael ;
Skene, Anthony ;
A'Hern, Roger ;
Salter, Janine ;
Detre, Simone ;
Hills, Margaret ;
Walsh, Geraldine .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (02) :167-170
[10]   Role of estrogen receptor gene demethylation and DNA methyltransferase DNA adduct formation in 5-aza-2′-deoxycytidine-induced cytotoxicity in human breast cancer cells [J].
Ferguson, AT ;
Vertino, PM ;
Spitzner, JR ;
Baylin, SB ;
Muller, MT ;
Davidson, NE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (51) :32260-32266